In this educational podcast discussion, Carlos M. De Castro, MD, and David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath, explore paroxysmal nocturnal hemoglobinuria (PNH). They trace the evolution of treatment from early complement inhibitors to today’s expanding therapeutic options, emphasizing how these advances have transformed patient outcomes and quality of life. The conversation blends clinical insights with practical considerations for therapy selection and patient care, including: The pathogenesis of PNH and the role of complement activation Landmark therapies such as eculizumab and ravulizumab Advances in proximal inhibitors (eg, pegcetacoplan, iptacopan, danicopan) Quality-of-life considerations, treatment personalization, and emerging therapies Presenters: Carlos M. De Castro, MD Professor of Medicine, DUMC Division of Malignant Hematology and Cellular Therapy Department of Medicine Duke University Duke Cancer Institute Durham, North Carolina David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath Consultant Hematologist and Director of Bone Marrow Transplant Program Professor of Medicine Division of Hematology Mayo Clinic College of Medicine and Science Rochester, Minnesota Link to full program: https://bit.ly/3Jtjqgr Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
